On the other hand, DHMEQ treatment was able to reduce in dose-dependent manner the expression of the metastasis-promoting genes MMP-2, MMP-14, TIMP-2, and uPA, all of which have been implicated in the regulation of invasion in glioma cells [45–48]. The gene discussed is MMP2; the disease is glioma.